Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Antigenic Divergence and Functional Antibody Responses in Emerging Orthopoxvirus Cross-Protection

Award Number: F31AI194693
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 02/21/2027
PERIOD OF PERFORMANCE END DATE: 02/20/2028

Group Awards By:

View Award Description

Antigenic Divergence and Functional Antibody Responses in Emerging Orthopoxvirus Cross-Protection - ABSTRACT Since the eradication of smallpox in 1980, monkeypox (MPXV) has emerged as the most prominent human orthopoxvirus infection globally. Historically confined to Central and West Africa with primarily zoonotic transmission, recent emerging strains have demonstrated unprecedented transmission dynamics characterized by sustained human-to-human transmission and geographic spread outside Africa, exemplified by Clade Ib MPXV's recent local transmission in California as of October 2025. The increased lethality of Clade Ib compared to Clade IIb further underscores the escalating public health threat posed by these emerging orthopoxviruses, alongside other divergent threats such as the recently discovered borealpox. Despite maintaining a high degree of genetic similarity across the orthopoxvirus genus, vaccine mediated cross-protection is unpredictable and declines with antigenic distance, limiting pandemic preparedness. My previous work demonstrates that current smallpox vaccines (MVA-BN) elicit only moderate and short-lived antibody responses against antigenically distant MPXV Clade IIb, with neutralization capacity declining further against more distant viruses like Clade Ib MPXV and borealpox. However, the mechanistic basis of cross-protective immunity when neutralizing responses fail remains undefined. To define the breadth and limitations of orthopoxvirus vaccine protection, this proposal includes borealpox as the most highly divergent human-infecting orthopoxvirus, serving as the upper limit for understanding cross-protective immunity across the genus. This research investigates how antigenic divergence across orthopoxviruses relates to functional antibody responses and identifies non-neutralizing mechanisms that compensate when neutralization is reduced. Aim 1 characterizes antigenic divergence through sequence analysis and in silico epitope prediction, then validates findings using recombinant protein ELISAs and neutralization assays against VACV, Clade Ib MPXV, Clade IIb MPXV, and borealpox. Aim 2 identifies non- neutralizing Fc-effector mechanisms (complement-mediated neutralization and FcγRIIIa-ADCC) that mediate cross-protection when baseline neutralization is weak. Integration of computational and functional data will define functional immune profiles revealing how antigenic distance drives shifts from neutralization-dependent to Fc- effector-dependent immunity. These findings will directly inform rational vaccine redesign strategies for emerging orthopoxvirus threats and enhance pandemic preparedness.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $50,114 )
2026	2026	YALE UNIV	150 MUNSON ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Allergy and Infectious Diseases Research	000	1	8/21/2026	NEW	$50,114
														Subtotal = $50,114

Grand Total All Awards = $50,114

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Antigenic Divergence and Functional Antibody Responses in Emerging Orthopoxvirus Cross-Protection

Award Number: F31AI194693

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 02/21/2027

PERIOD OF PERFORMANCE END DATE: 02/20/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer